Mechanism of Action

Tremfya works by targeting IL-23, a cytokine involved in the differentiation and activation of T-helper cells, which play a central role in the inflammatory processes of autoimmune diseases. By inhibiting IL-23, Tremfya helps to reduce the inflammatory response associated with these conditions .

Indications

Tremfya is indicated for the treatment of

• Plaque Psoriasis: Adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

• Psoriatic Arthritis: Adults with active psoriatic arthritis.

• Crohn’s Disease: Adults with moderately to severely active Crohn’s disease.

• Ulcerative Colitis: Adults with moderately to severely active ulcerative colitis 

Administration & Dosing

Tremfya is administered as a subcutaneous injection. The dosing schedule typically involves an initial dose, followed by maintenance doses every 8 weeks. Specific dosing schedules may vary based on the condition being treated and individual patient factors .

Side Effects

Common side effects of Tremfya may include:

• Respiratory tract infections

• Headache

• Injection site reactions

• Joint pain (arthralgia)

• Diarrhea

• Stomach flu (gastroenteritis)

• Fungal skin infections

• Herpes simplex infections

• Stomach pain

• Bronchitis 

Patients should be monitored for signs of infection and other potential adverse effects during treatment.